Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Up 58.7% in October

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the target of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 160,100 shares, a growth of 58.7% from the October 15th total of 100,900 shares. Based on an average daily trading volume, of 117,900 shares, the days-to-cover ratio is presently 1.4 days.

Enlivex Therapeutics Stock Performance

Shares of ENLV traded down $0.10 during trading hours on Thursday, hitting $1.08. 158,627 shares of the company were exchanged, compared to its average volume of 117,266. The firm’s 50 day moving average is $1.45 and its 200-day moving average is $1.40. Enlivex Therapeutics has a 52 week low of $1.08 and a 52 week high of $4.59. The company has a market cap of $23.12 million, a PE ratio of -0.92 and a beta of 1.11.

Enlivex Therapeutics (NASDAQ:ENLV) last announced its quarterly earnings data on Friday, August 30th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06. As a group, equities analysts forecast that Enlivex Therapeutics will post -0.7 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. XTX Topco Ltd acquired a new stake in shares of Enlivex Therapeutics in the 2nd quarter valued at about $35,000. Sigma Investment Counselors Inc. bought a new position in shares of Enlivex Therapeutics during the 3rd quarter worth approximately $50,000. Finally, Armistice Capital LLC bought a new stake in shares of Enlivex Therapeutics in the 2nd quarter worth approximately $2,415,000. 1.02% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ENLV. EF Hutton Acquisition Co. I upgraded Enlivex Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 27th. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Enlivex Therapeutics in a research note on Friday, September 27th.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.